Vertex Pharmaceuticals (VRTX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the ...

Deep-pocketed investors have adopted a bullish approach towards Vertex Pharmaceuticals VRTX, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

VRTX will need to target hospitals and surgical centers as well as physicians' offices. Marketing will involve working with hospitals to gain formulary access through the Pharmacy & Therapeutics ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Average portfolio weight of all funds dedicated to VRTX is 0.51%, an increase of 5.07%. Total shares owned by institutions increased in the last three months by 1.10% to 287,243K shares.

UBS has resumed coverage of Vertex Pharmaceuticals (NASDAQ:VRTX) with a buy rating, citing the company's growth potential. The investment bank said it believes Vertex (VRTX) has “best in sector ...

Fintel reports that on October 16, 2024, Scotiabank initiated coverage of Vertex Pharmaceuticals (WBAG:VRTX) with a Sector Perform recommendation. There are 2,817 funds or institutions reporting ...